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ABSTRACT
Background. The thyroid cancer incidence is rising. Despite
current guidelines, controversy exists regarding the degree and
duration of thyrotropin suppression therapy. Also, its potential
skeletal effects remain a concern tophysicians caring for thyroid
cancer patients. We conducted a review of published data to
evaluate existing studies focusing on the skeletal effects of
thyrotropin suppression therapy in thyroid cancer patients.
Materials and Methods. A systematic search of the PubMed,
Ovid/Medline, and Cochrane Central Register of Controlled
Trials databases was conducted. The retained studies were
evaluated for methodological quality, and the study popula-
tions were categorized into premenopausal women, post-
menopausal women, and men.
Results. Twenty-five pertinent studies were included. Seven
studies were longitudinal and 18 were cross-sectional. Of
the 25 included studies, 13 were assigned an excellent
methodological quality score. Three of 5 longitudinal studies and
3 of 13 cross-sectional studies reported decreased bone mineral
density (BMD) in premenopausal women; 2 of 4 longitudinal
studies and 5 of 13 cross-sectional studies reported decreased
BMD in postmenopausal women. The remaining studies
showed no effect on BMD.The only longitudinal study ofmen
showed bone mass loss; however, cross-sectional studies of
men did not demonstrate a similar effect.
Conclusion. Studies to date have yielded conflicting results on
the skeletal effects of thyrotropin suppression therapy and a
knowledge gap remains, especially for older adults and men.
Existing data should be cautiously interpreted because of the
variable quality andheterogeneity. Identifying groups at riskof
adverse effects from thyrotropin suppression therapy will be
instrumental to providing focused and tailored thyroid cancer
treatment. The Oncologist 2016;21:165–171
Implications for Practice: The standard treatment for thyroid cancer includes total thyroidectomy with or without radioactive
iodine ablation, often followed by thyrotropin suppression therapy. Despite current guidelines, controversy exists regarding the
degree anddurationof thyrotropin suppression therapy, anddiscordant results havebeen reportedon its adverseeffects onbone.
The present review provides physicians with existing data on the skeletal effects of thyrotropin suppression therapy, highlighting
theneed for further research to identify the groups at riskof adverse skeletal effects.This knowledgewill aid in developing tailored
thyroid cancer treatment.
INTRODUCTION
The incidence of thyroid cancer is rising in the United States,
withanestimated62,450newcases in2015 [1].The incidence
is highest in older adults [1], the same cohort at greatest
risk of adverse events from thyroid hormone suppression
therapy. The standard treatment for differentiated thyroid
cancer includes total thyroidectomy with or without
radioactive iodine ablation, followed by thyrotropin (TSH)
suppression therapy in most cases [2]. Experimental studies
and clinical data have demonstrated that thyroid cell
proliferation is TSH-dependent [3, 4]. This provides a rationale
for TSH suppression as a treatment modality for differenti-
ated thyroid cancer to inhibit growth of residual neoplas-
tic thyroid tissue. Current American Thyroid Association
guidelines recommend initial TSH suppression to less than
0.1 mIU/L for patients with high-risk well-differentiated
thyroid cancer. Also,maintenance of the TSHat or slightly less
than the lower limit of normal (0.1–0.5 mIU/L) is considered
appropriate for low-risk and intermediate-risk patients [2].
Despite the current guidelines, controversy remains regard-
ing the appropriate use of thyrotropin suppression therapy,
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including the degree of TSH suppression and duration of
therapy.
Thyrotropin suppression therapy induces a state of
subclinical hyperthyroidism. It hasbeen recognized thatexcess
thyroid hormone and the absence of TSH-mediated osteoclast
suppression stimulate bone resorption [5, 6]. This leads to
increased bone turnover and decreased bone mineral density
(BMD), thus increasing the risk of fractures [6]. This is
important, because most patients with differentiated thyroid
cancer have a favorable prognosis, with patients living long
enough to develop bone loss later in life.
We conducted a comprehensive literature review to
identify those studies that examined the skeletal effects of
thyrotropin suppression therapy in the treatment of differen-
tiated thyroid cancer.We systematically reviewed these studies
to determine the gaps in knowledge for population subgroups.
MATERIALS AND METHODS
Data Sources and Searches
The PubMed, Ovid/Medline, and Cochrane Central Register of
Controlled Trials (CENTRAL) were searched to identify pertinent
studies for review. The medical subheading terms used included
thyrotropin,thyroidneoplasms, risk,boneandbones,bonedensity,
and adverse effects. Other keywords included fracture(s),
skeletal, TSH suppression, and levothyroxine treatment. The
citation abstracts identified in the searches were reviewed in
detail to determine their relevance for inclusion in the review.
A careful review of the reference lists of the retained studies
was also performed to identify other salient studies.
Study Selection
Studies were included in the review if they fulfilled the following
eligibility criteria: published in English, evaluated thyrotropin
suppressiontherapy inpatientswiththyroidcancer,andreported
skeletal outcome measures (including bone mineral density,
bone mass, bone turnover markers, and fractures). Studies that
evaluated the effects of thyrotropin suppression therapy in
patientswithbenignthyroiddiseaseortheeffectsofendogenous
subclinical or overt hyperthyroidism were excluded. Studies
conducted in the pediatric population were also excluded.
Data Abstraction
The abstracted information from each retained report in-
cluded (a) study design and sample size, (b) characteristics of
the study sample (e.g.,meanage, sex), (c)menopausal status if
the sample included female patients, (d) outcome measure
variables on skeletal risk (e.g., bonemineral density at various
sites, bone turnover markers), and (e) secondary outcomes, if
present (e.g., duration of thyroid hormone suppression
treatment). For the purposes of the present review, the study
populations were categorized into premenopausal women,
postmenopausal women, and men.
Quality Assessment
The retained studies were evaluated for methodological
quality using a standardized validated instrument, addressing
reporting quality, external validity, bias, confounding factors,
and the power of the randomized and nonrandomized studies
[7]. Threshold scores were used to assign a quality score of
“excellent.”Ascore of$12 (score range, 0–32)was considered
excellent [7].
RESULTS
Study Characteristics and Quality
Of the initial 384 studies identified, 25 addressed the effect of
thyrotropinsuppression therapyonbonequality in thyroidcancer
patients and were included in the present review. Of the 25
studies,7were longitudinal and18werecross-sectional indesign.
Thepatients forall thestudieshadbeenrecruitedfromoutpatient
clinics. Only 6 of the retained articles included all 3 population
groups (premenopausal women, postmenopausal women, and
men) [8–13]. Although several of the reviewed studies included
patients.65 years old, none of themhad specifically focused on
older adults, and only one study’s participants had a mean age
.65years,whichwasinthegroupofpostmenopausalwomen[8].
Of the 25 included studies [8–32], 13 were assigned an
excellent methodological quality score, with a median quality
score of 13 (score range, 6–20) [8, 10, 15–17, 19, 22, 24–26,
29–31] (Tables 1–3).
Studies of Premenopausal Women
Atotal of18studies includedpremenopausalwomenreceiving
thyrotropin suppression therapy for differentiated thyroid
cancer, and these studies are summarized in Table 1 [8–25]. Of
these 18 studies, 5 were longitudinal and 13 were cross-
sectional in design. Their findings showed conflicting results,
with 12 studies showing no significant change and 6 showing a
decrease in bone mineral density.
A recent longitudinal study with a mean follow-up of 6.5
years showed that the risk of postoperative osteoporosis in
women with low- or intermediate-risk thyroid cancer, adjusted
for age, increased fourfoldwhen their TSHwas suppressed long-
term,withoutdecreasingcancer recurrence [25]. Jo´daretal. [17]
conducted a longitudinal study of 37 premenopausal women,
who had been receiving thyrotropin suppression therapy for a
mean of 5.6 years.They found no difference in the bonemineral
density at the lumbar spine, femoral neck, or Ward’s triangle.
They did, however, find a small, but statistically significant,
reduction at the distal ulna, but this was considered minimal
when compared with the controls [17]. Two other longitudinal
studies showed similar findings (i.e., no difference was found in
bonemineraldensitywhencomparedwiththecontrols) [18,20].
Neitherstudyshowedachange inbonemineraldensitybetween
theinitialandfollow-upbonemineraldensityscans. Incontrast,a
smaller longitudinal study [22] (n 5 8) found a significant
reduction in bonemineral density in the lumbar spine 1–3 years
after the initiation of thyrotropin suppression therapy.
Most cross-sectional studies did not find a significant
change in bone mineral density in premenopausal women
[8–14, 16, 19, 24] (Table 1). The largest of these [14] was a
Taiwanese retrospective study (n 5 44) in which the bone
density was measured at the lumbar spine, femoral neck,
Ward’s triangle, and total hip, following an average of 7.3 years
of thyrotropin suppression therapy. No significant change was
seen in bone density at all sites between patients and the age-
and body mass index-matched controls. No correlation was
found between the bone mineral density and the degree of
thyrotropin suppression or duration of levothyroxine therapy.
©AlphaMed Press 2016
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Table 1. Summary of studies investigating effect of thyrotropin suppression therapy in premenopausal female thyroid cancer
patients on bone
Study
Sample
size (n) Agea (yr)
Patients
with TSH
suppression
(%) Control group Effect/outcome
Length of
thyroid
hormone
treatmenta (yr)
Longitudinal
Wang et al. [25]b,c 569 486 14 62 Thyroid cancer, female
patients with TSH.0.4
postoperatively
Osteoporosis (T score
#2.5)
6.5 (median)
Jo´dar et al. [17]b 37 476 13 50 Healthy, matched for age,
sex, weight, menopausal
status
Decrease in distal
radius BMD
5.66 3.2
Karner et al. [18] 19 396 8.0 100 None No change in BMD 9.46 6.4
Muller et al. [20] 15 476 3.0 40 Healthy, matched for age,
sex, BMI, menopausal
status
No change in BMD 11
Pioli et al. [22]b 8 436 6.8 100 Healthy, matched for age,
sex, menopausal status
Decrease in spine BMD 1–3 (range)
Cross-sectional
Chen et al. [14] 44 38.66 6.7 100 Healthy, matched for age,
sex, BMI, menopausal
status
No change in BMD 7.36 3.0
Tournis et al. [24]b 40 40.26 6.4 100 Healthy, matched for age,
sex, BMI, menopausal
status,
calcium intake
No change in markers
of bone resorption or
bone formation, no
change in BMD
4.4
Marcocci et al. [19]b 38 39 95 Healthy, matched for age,
sex, weight
No change in BMD 10.1
Heijckmann et al.
[10]b
26 406 7.0 100 None No change in BMD 4
Lehmke et al. [11] 25 496 16.0 100 None No change in BMD 56 4.3
Stepan et al. [12] 20 40.46 5.9 100 None No change in vertebral
BMD or biochemical
indexes of bone
resorption
and osteoblastic activity
6.06 5.1
Franklyn et al. [8]b 18 41.16 4.9 72 Healthy, matched for age,
sex, BMI, menopausal
status,
smoking, calcium intake
No change in BMD 7.7
Toivonen et al. [13] 15 45 (median) 100 Healthy, matched for age,
sex
Increased markers of
bone formation and
bone resorption, no
change in BMD
9–11 (range)
Go¨rres et al. [9] 15 35.56 6.0 93 Healthy, matched for age,
sex
No change in BMD 5
Diamond et al. [15]b 14 41.66 1.9 100 Healthy, matched for age,
sex, BMI, menopausal
status
Decrease in femoral
neck BMD
10.76 1.7
Giannini et al. [16]b 12 41/16 2.0 100 Healthy, matched for age,
sex
No change in BMD 9.25
Paul et al. [21] 5 36.561.2 100 Healthy, matched for age,
sex, weight
Decrease in femoral
neck and femoral
trochanter BMD
9.26 1.0
Ross et al. [23] 4 376 4.0 NA Healthy, matched for age,
sex, menopausal status
Decrease in BMD $5
Abbreviations:BMD,bonemineraldensity;BMI,bodymass index;NA,notapplicable (the investigatorshaddocumentedthat,overall, 82%ofpatientshad
suppressed TSH; however, they did not specify whether this included the patients with thyroid cancer); TSH, thyrotropin.
aData presented as mean6 SD, unless otherwise noted.
bExcellent methodological quality per Downs and Black [7].
cMenopausal status not reported; because of the mean age, most patients included were assumed to be premenopausal.
www.TheOncologist.com ©AlphaMed Press 2016
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Three small cross-sectional studies demonstrated a de-
crease in bone mineral density with thyrotropin suppression
therapy of varying duration [15, 21, 23]. The largest of
these studied 14 premenopausal women with differentiated
thyroid cancer inAustraliawhohadbeen receiving thyrotropin
suppression therapy for at least 5 years [15]. None of the
patients had been taking estrogen, calcium, or vitamin D
supplementation. Compared with the controls matched for
age and menopausal status, the patients were found to have
decreased bonemineral density in the femoral neck but not in
the lumbar spine or forearm.
A few studies also examined the effect of thyrotropin
suppression therapy on markers of bone turnover in premeno-
pausal women [12, 13, 24]. Only one study found a significant
increase in both markers of bone formation and resorption;
however, no change in bone mineral density was seen [13].
Studies of Postmenopausal Women
A total of 17 studies included postmenopausal women [8–17,
20, 24, 26–30] (Table 2). Of these, 4 were longitudinal and 13
cross-sectional in design.
The largest longitudinal study (n 5 120) showed de-
creased bonemineral density only in women aged$50 years
receiving thyrotropin suppression therapy compared with
women with thyroid cancer who had normal TSH levels
postoperatively at 1 and 5 years of follow-up [29]. A
longitudinal study by Jo´dar et al. found a decrease in bone
mineral density at the distal radius but not at any other site in
39 postmenopausal women [17]. This finding was similar to
their finding in the cohort of premenopausal women [17].
However, only 50% of the cohort had a level of TSH
suppression of ,0.1 mIU/L. Also, the absolute numbers
compared with those in the controls were not reported.
Another longitudinal trial [26] reported no change in bone
mineral density over 2 years in postmenopausal women
receiving thyrotropin suppression therapy for an average of 7
years. A smaller longitudinal study also did not report a
change in bone mineral density [20].
Cross-sectional studies have yielded inconsistent results.
The largest of these studies [30] included 109 postmenopausal
women and found no significant differences between the
lumbaror femoralTscore forpatientsandage-matchedcontrols
after an average of 7.3 years of thyrotropin suppression therapy.
Several other cross-sectional studies did not demonstrate a
change in bone mineral density in postmenopausal women
receiving thyrotropin suppression therapy [8–10, 13, 16, 24, 27].
However, twoof thesedemonstrated an increase inmarkers of
bone resorption [13, 24] (Table 2). Kung et al. [28] found a
significant reduction in bone mineral density at all measured
sites (femoralneck, femoral trochanter,Ward’striangle, lumbar
spine) in southern Chinese postmenopausal women (n5 34)
after an average of 12.2 years of thyrotropin suppression
therapy. The patients were matched for age and menopausal
status. The investigators noted two fractures in the treatment
group compared with none in the control group, as well as
increased osteocalcin levels. Four smaller cross-sectional
studies also reported decreased bone mineral density at
different measured sites in patients [11, 12, 14, 15]; however,
two of these lacked control groups [11, 12] (Table 2). Several
other cross-sectional studies did not demonstrate a change in
bone mineral density in postmenopausal women receiving
thyrotropin suppression therapy (Table 2).
Studies of Men
Nine of the reviewed studies included men [8–13, 18, 31, 32]
(Table 3). All except one study [18] were cross-sectional
studies, and all had a small sample size (n 5 4–33). The only
longitudinal study was conducted by Karner et al. [18]. Their
study included 9 men with thyroid cancer. They performed an
initial bone mineral density measurement after an average of
8.1 years of thyrotropin suppression therapy, with a follow-up
bonemineral densitymeasurement taken 1 year later [18]. No
significantdifferencewas found inbonemineral density values
from the first and second measurements for the lumbar spine
and femoral neck, although a statistically significant difference
was demonstrated at the distal radius. However, no control
groups were included in their study [18].
None of the cross-sectional studies that included men
found a change in bone mineral density in male patients with
thyroid cancer receiving thyrotropin suppression therapy of
variable duration [8–13, 31, 32]. Two of these studies lacked a
control group [11, 12] (Table 3). One small cross-sectional
study (n 5 4), in which men underwent thyrotropin
suppression therapy for a range of 9–11 years, found an
increase in both bone formation and bone resorptionmarkers
but no change in bone mineral density [13].
DISCUSSION
To prevent thyroid cancer recurrence, thyrotropin suppression
therapyhasbeenrecommendedforpatientswith intermediate-
and high-risk well-differentiated thyroid cancer after surgical
resectionandradioactive iodineablation[2].Despitethisclinical
practice, consensus is lacking regarding the optimal TSH
concentration to reduce cancer recurrence and minimize the
toxicity from exogenous subclinical hyperthyroidism. In
addition, the optimal duration of thyrotropin suppression
therapy remains unknown. Biondi and Cooper suggested a
risk-adapted approach, in which the potential benefits of
thyrotropin suppression therapy were weighed against its
potential adverse effects, taking into account age and comor-
bidities [33]. However, to date, no age-specific guidelines exist.
The present review has shown that existing studies on the
effect of thyrotropin suppression therapy on bone in thyroid
cancer patients have yielded conflicting results. This is largely
because of differences in study design, study population,
methodology, degree of TSH suppression, follow-up duration,
and measured outcomes. In addition, most of the studies
reviewedwere limitedbyasmall samplesize, insufficientpower,
and varying degrees of control for confounding variables.
The relationship between exogenous subclinical hyperthy-
roidism and skeletal integrity remains controversial. The data
obtained from previous studies on the effect of thyrotropin
suppressiontherapyinthyroidcancerpatientsdemonstratedno
deleterious consequences in premenopausal women. How-
ever, these data suggest that postmenopausal women might
constitute a risk group for decreased bonemineral density.
Data frommenare scarce, as evidencedby the small sample
sizes of the studies that included men. This was most likely
because of the lower incidence of differentiated thyroid
cancer in this population. However, despite the notion that
©AlphaMed Press 2016
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osteoporosis is thought to affect predominantly women, it has
recently been shown that it is underdiagnosed and under-
treated inoldermen, leavingthemvulnerable toearlydeathand
disability [34]. A need exists to address the gap in knowledge
regarding the influence of thyrotropin suppression therapy on
bone quality in the male population. Only a few studies have
Table 2. Summary of studies investigating effect of thyrotropin suppression therapy in postmenopausal female thyroid cancer
patients on bone
Study
Sample
size (n)
Mean
agea (yr)
Patients
with TSH
suppression
(%) Control group Effect/outcome
Length of
thyroid
hormone
treatmenta (yr)
Longitudinal
Sugitani et al. [29]b,c 120 50.26 13.3 100 Thyroid cancer, female
patients with normal
TSH postoperatively
Decrease in BMD in
women aged$ 50 y
5
Jo´dar et al. [17]b 39 476 13 50 Healthy, matched for age,
sex, weight, menopausal
status
Decrease in distal
radius BMD
5.66 3.2
Guo et al. [26]b 23 616 9.0 100 Healthy, matched for age,
sex, menopausal status
No change in BMD
Muller et al. [20] 10 476 3.0 40 Healthy, matched for age,
sex, BMI, menopausal
status
No change in BMD 11
Cross-sectional
De Melo et al. [30]b 109 58.46 8.3 100 Healthy, matched for age No change in BMD 7.36 5.9
Tournis et al. [24]b 40 56.76 3.9 100 Healthy, matched for age,
sex, BMI, menopausal
status, calcium intake
Increase in bone
resorption markers, no
change in bone formation
markers, no change in
BMD
5
Kung et al. [28] 34 626 8.0 100 Healthy, matched for age,
sex
Decrease in spine, femoral
neck, and hip BMD
12.26 6.6
Go¨rres et al. [9] 32 60.86 11.4 96 Healthy, matched for age,
sex
No change in BMD 11.16 6.1
Chen et al. [14] 25 57.76 6.9 100 Healthy, matched for age,
sex, BMI, menopausal
status
Decrease in lumbar spine,
femoral neck, total hip
BMD
7.36 3.0
Stepan et al. [12] 25 60.46 9.6 100 None Decrease in vertebral
BMD,
increase in biochemical
indexes of bone
resorption
and osteoblastic activity
6.06 5.1
Hawkins et al. [27] 21 59.66 7.5 80 Healthy, matched for sex,
menopausal status
No change in BMD 6.26 2.2
Lehmke et al. [11] 16 496 16.0 100 None Decrease in calcaneus and
midshaft radius BMD
56 4.3
Heijckmannetal. [10]b 14 636 9.0 100 None No change in BMD 5.5
Giannini et al. [16]b 13 57.66 1.7 100 Healthy, matched for age,
sex
No change in BMD 7.6
Toivonen et al. [13] 10 45 (median) 100 Healthy, matched for age,
sex
Increased bone formation
and resorption markers,
no change in BMD
9-11 (range)
Diamond et al. [15]b 10 596 2.8 100 Healthy, matched for age,
sex, BMI, menopausal
status
Decrease in spine, femoral
neck, and radius BMD
5.96 1.0
Franklyn et al. [8] 2 65.46 8.1 76 Healthy, matched for age,
sex, BMI, menopausal
status, smoking, calcium
intake
No change in BMD 8.1
Abbreviations: BMD, bone mineral density; BMI, body mass index; TSH, thyrotropin.
aData presented as mean6 SD, unless otherwise noted.
bExcellent methodological quality per Downs and Black [7].
cRandomized controlled trial;menopausal statusnot reported;mean age50.2613.3 years; patients aged$80 years and thosewith severe osteoporosis
were excluded.
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been conducted to date on the effect of subclinical hyperthy-
roidism secondary to thyrotropin suppression therapy for
differentiated thyroid cancer on bone in men, and all of them
have been of poor quality and underpowered. Only one
longitudinal studyhasbeenconductedtodate inmen;however,
it hada small sample size (n59)and lackedacontrolgroup [18].
Existingcross-sectional studiesofmenhavealsobeen limitedby
inadequate power and some lacked control groups. The risk of
vertebral fractures inmen has been shown to be as high as one
half the rate seen in women; however, men and women
experience equal morbidity from them [35]. In addition, men
have been shown to sustain fractures at a higher bone mineral
density than women, and the mortality in the year after a hip
fracture has been twice as high as that in women [36–39].
Also, a need exists to delineate the implications of long-term
thyrotropin suppression therapy on bone health in older adults
(age .65 years) with thyroid cancer. Although several studies
have included patients aged$65 years, none of the studies to
date have focused exclusively on older adults (age.65 years) or
theoldestadults (age.80years).Becausethisoldercohort isthe
most vulnerable tobone loss and fracture risk, treatment targets
with thyroid hormone replacement therapy might need to be
modified in these patients to minimize adverse skeletal effects.
Exogenous subclinical hyperthyroidism in thyroid cancer
patients and its potential effects onbonehealth remain a concern
to physicians involved in the long-term care of these patients.
Identifying the groups at risk of adverse effects from treatment is
key to tailoring therapy and guiding clinical practice in a more
focused pattern, rather than a “one size fits all” approach. Future
research, includinglongitudinalstudiesandrandomizedcontrolled
trials, isneeded toprovide further insight into theskeletaleffectof
thyrotropin suppression therapy in different subgroups of thyroid
cancer patients. Further studies are also needed to evaluate the
potential effect of exogenous subclinical hyperthyroidism in
female andmale thyroid cancer patients aged$65 years.
CONCLUSION
The standard treatment for differentiated thyroid cancer
includes total thyroidectomywith orwithout radioactive iodine
ablation, often followed by TSH suppression therapy. Studies to
datehaveyieldedconflictingresultsontheeffectsofthyrotropin
suppressiontherapyforthetreatmentofthyroidcanceronbone
density. A large gap exists in knowledge, especially for older
adultsandmenwiththyroidcancer. Identifyingthegroupsatrisk
of adverse effects of thyrotropin suppression therapy is
instrumental to providing focused and tailored therapy.
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